Exact Sciences has introduced its Oncotype MAP Pan-Cancer Tissue test for patients with advanced, metastatic, refractory or recurrent cancer, the company announced today.

According to a release, the Oncotype MAP test provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient’s tumor profile and effectively recommend targeted therapies or clinical trials.

“Exact Sciences is pursuing life-changing answers that give people the clarity to take action earlier,” Exact Sciences CEO Kevin Conroy said in a statement. “Our growing Precision Oncology portfolio and the addition of the Oncotype MAP test allow us to do just that for patients fighting late-stage or metastatic cancer.”

The test, which is covered by Medicare, is currently available for physicians in the United States.